Clinical Trial Update: Neoadjuvant Chemotherapy and Tilelizumab in Stage III（cTNM-IIIA.IIIB）Non-small-cell Lung Cancer [Phase 2]

View source ↗

Summary

Clinical trial update for neoadjuvant chemotherapy with Tilelizumab in stage III non-small-cell lung cancer (Phase 2).

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Non-small Cell Lung Cancer

Drugs mentioned

• Tilelizumab (Tilelizumab)

Snippet

Sponsor: West China Hospital | Conditions: Stage III, Non-small Cell Lung Cancer | Phase 2 | Status: UNKNOWN